Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ARO-MAPT

Oligonucleotide (siRNA) · Gene silencing: MAPT · developed by ARROWHEAD PHARMACEUTICALS

Phase 1/2 Most advanced trial

ARWR Developer

1 Registered trials

What is ARO-MAPT?

ARO-MAPT is a small interfering RNA (siRNA) that reduces MAPT (tau) protein production. It is administered by subcutaneous injection and is being studied in Alzheimer disease, including early-onset forms.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Oligonucleotide (siRNA)
Targets: MAPT
Mechanism: Gene silencing: MAPT
Therapy area: Neurology
Developer: ARROWHEAD PHARMACEUTICALS (ARWR)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07221344	Phase 1/2	Alzheimer Disease	Recruiting	ARWR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer DiseaseAlzheimer Disease, Early Onset

More from ARROWHEAD PHARMACEUTICALS

Plozasiran FDA approved ARC-521 Phase 1 ARC-AAT Phase 2 ARO-033 Phase 1 ARO-ALK7 Phase 1/2 ARO-ANG 3 Phase 2 ARO-APOC3 Phase 2 ARO-ATXN2 Phase 1 ARO-C3 Phase 1/2 ARO-CFB Phase 1 ARO-DIMERPA Phase 1/2 ARO-ENaC Phase 1/2

Sources

ClinicalTrials.gov NCT07221344

Updated Oct 3, 2026. Something wrong or missing? Report it on the ARWR page.

Follow ARWR, the company behind ARO-MAPT

See ARWR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARWR catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z